Biomedical Occupation or Discipline – Page 39

AbbVie Secures Deal with Medincell for Long-Acting Injectable Platform, Valued up to $1.9 Billion

1 year ago talkbio0Tagged AbbVie, Biotechnology, long-acting injectable platform, Medincell

AbbVie, Medincell, Long-acting injectable platform, Biotechnology, Deal, $1.9 billion

FDA Launches CDER Center for Clinical Trial Innovation (C3TI) to Boost Trial Design and Efficiency

1 year ago talkbio0Tagged C3TI, Center for Drug Evaluation, Center for Drug Evaluation and Research, Clinical Trial Innovation, Clinical Trials, Collaboration, Drug Development, Efficiency, innovation, research, United States Food and Drug Administration

FDA, CDER (Center for Drug Evaluation and Research), C3TI (CDER Center for Clinical Trial Innovation), Clinical trial innovation, Efficiency, Drug development, Trial design, Collaboration

Cullinan Secures $280M in Private Placement to Enter Autoimmune Market

1 year ago talkbio0Tagged autoimmune market, Biotechnology, Cullinan, private placement

Cullinan, Private Placement, $280M, Autoimmune Market, Biotechnology

Fujifilm Diosynth Announces $1.2B Expansion in North Carolina, Aiming to Employ 1,400

1 year ago talkbio0Tagged Biopharmaceutical manufacturing, Biotechnology, CDMO facility, end-to-end cell culture, expansion, Fujifilm, Holly Springs, Investments, Japanese language, North Carolina, Occupations

Fujifilm Diosynth Biotechnologies, $1.2 billion expansion, North Carolina, Holly Springs, 1/400 jobs, Biopharmaceutical manufacturing, End-to-end cell culture CDMO facility, Japanese investment

Vertex Acquires Alpine Immune Sciences for $4.9 Billion to Boost Immunology Trail

1 year ago talkbio0Tagged Acquisition (action), Alpine Immune Sciences, Immunology, TNFSF10 protein, human

Vertex Pharmaceuticals, Alpine Immune Sciences, $4.9 billion acquisition, Immunology trail

Alexion Expands Indications for Long-Acting C5 Complement Inhibitor Ultomiris in Rare Autoimmune Disorder NMOSD

1 year ago talkbio0Tagged Alexion, Annals, Approved, AstraZeneca Rare Disease, C5 complement inhibitor, CHAMPIER-NMOSD trial, generalised myasthenia gravis, gMG, long-acting, Marc Dunoyer, Neurology speciality, Neuromyelitis Optica, Paroxysmal nocturnal hemoglobinuria, Publications, ravulizumab-cwvz, Ultomiris, United States Food and Drug Administration

Ultomiris, ravulizumab-cwvz, C5 complement inhibitor, neuromyelitis optica spectrum disorder (NMOSD), FDA approval, long-acting, zero relapses, CHAMPIER-NMOSD trial, Annals of Neurology publication, Marc Dunoyer, AstraZeneca Rare Disease, Alexion, generalised myasthenia gravis (gMG), paroxysmal nocturnal haemoglobinuria (PNH).